- Obesity From the People's Viewpoint
-
Park IR
- KMID: 2347601
- J Korean Med Assoc.
- 2002 May;45(5):612-616.
- doi: 10.5124/jkma.2002.45.5.612
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Medial Arterial Calcification and the Risk of Amputation of Diabetic Foot Ulcer in Patients With Diabetic Kidney Disease
-
So JM, Park JH, Kim JG, Park IR, Ha EY, Chung SM, Moon JS, Park CH, Yun WS, Kim TG, Kim W, Yoon JS, Won KC, Lee HW
- KMID: 2542597
- J Korean Med Sci.
- 2023 May;38(21):e160.
- doi: 10.3346/jkms.2023.38.e160
We assessed the risk factors for major amputation of diabetic foot ulcers (DFUs) in patients with diabetic kidney disease (DKD) stages 3b–5. For DFU assessment, in addition to DFU location... -
- CITED
-
- Close
- SHARE
-
- Close
- Usefulness of Fibrinogen B beta 448 Polymorphism as a Marker of Cerebral Infarction in Patients with Diabetes Mellitus
-
Son SY, Park IR, Woo JT, Kim SW, Yang IM, Kim JW, Kim YS, Choi YK, Pang JY
- KMID: 2306343
- Korean J Med.
- 1998 Nov;55(5):881-888.
OBJECTIVES: Cerebral infarction as a macrovascular complication in patients with diabetes mellitus is frequent. However, mechanisms for the development of cerebral infarction were not well known until today. The aims... -
- CITED
-
- Close
- SHARE
-
- Close
- Cispatin , Etoposide , Leucovorin and 5-Fluorouracil ( PELF ) Combination Chemotherapy for Advanced Gastric cancer: Interim Report
-
Park IR, Kim SY, Kim JH, Yoon HJ, Cho KS
- KMID: 2175331
- J Korean Cancer Assoc.
- 1998 Oct;30(5):907-913.
PURPOSE: In attempt to provide a feasible chemotherapeutic regimen for advanced gastric cancer patients, the combination of cisplatin, epirubicin, leucovorin and fluorouracil (PELF) has been developed. A trial was performed... -
- CITED
-
- Close
- SHARE
-
- Close
- Poor glycemic control is associated with the risk of subclinical hypothyroidism in patients with type 2 diabetes mellitus
-
Cho JH, Kim HJ, Lee JH, Park IR, Moon JS, Yoon JS, Lee IK, Won KC, Lee HW
- KMID: 2327746
- Korean J Intern Med.
- 2016 Jul;31(4):703-711.
- doi: 10.3904/kjim.2015.198
BACKGROUND/AIMS: Overt hypothyroidism is frequently found in patients with type 2 diabetes mellitus (T2DM), but it remains unknown the relationship between subclinical hypothyroidism (SCH) and T2DM. We attempt to evaluate... -
- CITED
-
- Close
- SHARE
-
- Close
- A Novel Index Using Soluble CD36 Is Associated with the Prevalence of Type 2 Diabetes Mellitus: Comparison Study with Triglyceride-Glucose Index
-
Kim HJ, Moon JS, Park IR, Kim JH, Yoon JS, Won KC, Lee HW
- KMID: 2389819
- Endocrinol Metab.
- 2017 Sep;32(3):375-382.
- doi: 10.3803/EnM.2017.32.3.375
BACKGROUND: Plasma soluble cluster determinant 36 (sCD36) level is closely related with insulin resistance and atherosclerosis, but little is known whether it could be a surrogate for estimating risk of... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension
-
Moon JS, Park IR, Kim HJ, Chung CH, Won KC, Han KA, Park CY, Won JC, Kim DJ, Koh GP, Kim ES, Yu JM, Hong EG, Lee CB, Yoon KH
- KMID: 2548157
- Diabetes Metab J.
- 2023 Nov;47(6):808-817.
- doi: 10.4093/dmj.2022.0387
Background: This study investigates the long-term efficacy and safety of evogliptin add-on therapy in patients with inadequately controlled type 2 diabetes mellitus (T2DM) previously received dapagliflozin and metformin (DAPA/MET) combination. Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
- The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study
-
Moon JS, Park IR, Kim SS, Kim HS, Kim NH, Kim SG, Ko SH, Lee JH, Lee I, Lee BK, Won KC
- KMID: 2548158
- Diabetes Metab J.
- 2023 Nov;47(6):818-825.
- doi: 10.4093/dmj.2023.0171
Background: To investigate the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe combination compared to highintensity rosuvastatin in high atherosclerotic cardiovascular disease (ASCVD) risk patients with type 2 diabetes mellitus (T2DM). Methods: This... -
- CITED
-
- Close
- SHARE
-
- Close
